Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer

Abstract

Breast cancer is classified into four major molecular subtypes, and is considered a heterogenous disease. The risk profiles and treatment of breast cancer differ according to these subtypes. Early detection dramatically improves the prospects of successful treatment, resulting in a reduction in overall mortality rates. However, almost 30% of women primarily diagnosed with the early-stage disease will eventually develop metastasis or resistance to chemotherapies. Immunotherapies are among the most promising cancer treatment options; however, long-term clinical benefit has only been observed in a small subset of responding patients. The current strategies for diagnosis and treatment rely heavily on histopathological examination and molecular diagnosis, disregarding the tumor microenvironment and microbiome involving cancer cells. In this review, we aim to praise the use of pharmacogenomics and pharmacomicrobiomics as a strategy to identify potential biomarkers for guiding and monitoring therapy in real-time. The finding of these biomarkers can be performed by studying the metabolism of drugs, more specifically, immunometabolism, and its relationship with the microbiome, without neglecting the information provided by genetics. A larger understanding of cancer biology has the potential to improve patient care, enable clinical decisions, and deliver personalized medicine.

The Interaction of SRL-2 Peptide with LRP-1 Receptor and Identification of Breast Cancer Related Biomarkers: An In-silico Approach

“…Integration of structural and computational methods is crucial for developing effective peptide-based drugs ( 16 ). Moreover, bioinformatics approaches can aid in identifying dependable biomarkers for breast cancer, resulting in timely detection, precise diagnosis, and efficient treatment ( 17 ). This highlights the requirement for novel therapeutic approaches founded on thoroughly comprehending the molecular pathways driving breast cancer’s onset, recurrence, and metastasis.…”

Action of Estrogen In Breast Cancer: A review Study

“…exemestane are being actively developed for breast cancer treatment. Aromatase inhibitors block both estrogen-dependent and independent pathways, and may lead to decreased motility rate (Costa & Vale, 2022).…”

Omics Technologies Improving Breast Cancer Research and Diagnostics

“…The conventional course of treatment for locally advanced BC is either surgery or mastectomy, with or without radiation. Although immunotherapy is one of the most promising cancer therapy choices, only a small subset of responding individuals have shown long-term therapeutic benefits [ 4 ].…”